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Abstract 
Objective: The objective of this article is to examine national trends in 
prescribing second-generation antipsychotic (SGA) medications to Australian 
children and youth (0–24 years) and to report deficiencies in available data.  
 
Methods: We conducted a retrospective review of government data on all 
dispensed SGA prescriptions between 2002 and 2007. Scripts were converted 
to defined daily dose (DDD)/1000 population/day using census data. Trends in 
utilisation of dispensed SGAs were analysed by gender and age.  
 Results: The total amount of SGAs dispensed to children (0–14 years) remained 
stable over the five-year study period. In 2007, according to available data, 
total SGA medication dispensed to Australian children equated to fewer than 
three in 10,000 children receiving the equivalent of a standard adult dose of 
medication each day.  
 
Conclusions: In contrast to many other countries, the dispensed use of SGA 
medication in Australian children and youth has remained relatively stable. In 
our opinion, this is almost certainly because of limitations in data collection 
and accessibility. Given the safety concerns associated with SGAs prescribed to 
children and young people and the need to improve the quality use of 
medicines, it is essential that methods are developed in Australia to accurately 
capture prescribing of SGAs to Australian children and youth.  
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The public subsidy of second-generation antipsychotic (SGA) medications for 
children and youth in Australia is supported by systematic reviews which have 
shown that SGAs are effective in treating schizophrenia, bipolar disorder, 
challenging behaviours, and disruptive and challenging behaviours in children 
and adolescents with autistic disorder and mental retardation.1–4  
 
There is growing critical opinion, however, that the early optimism that SGAs 
have better efficacy and fewer side effects than first-generation antipsychotics 
(FGA) has been misplaced.5 Despite the significantly increased cost, SGAs do 
not provide any therapeutic advantage over FGAs (e.g. haloperidol) in children 
and adolescents with psychotic disorders.6-8 Furthermore, SGAs produce 
serious adverse events that include weight gain, dyslipidaemia and insulin 
resistance.1,6  
 Internationally, the use of SGAs in children and adolescents has increased. In 
the United States (US), antipsychotic treatment in those aged 20 years or less 
increased five-fold between 1993 and 2002. Between 2000 and 2002, 92% of 
these prescriptions were for SGA medications.9 A cross-sectional US study 
reported that antipsychotic medication was prescribed to more than two 
million children and adolescent outpatients between 2003 and 2004.10 
Prescription rates have also increased in the United Kingdom (UK): between 
1992 and 2005 the prevalence of antipsychotic use in those aged 0 to 18 
almost doubled from 0.39 to 0.77 users per 1000 patient-years (U/1000PY). 
Most notably, there was almost a three-fold increase in the use of 
antipsychotics in children aged 7 to 12 years from 0.23 to 0.61 U/1000PY.11  
 
To date no Australian studies have examined national trends in antipsychotic 
medications dispensed to children and youth. In Australia, the cost of some 
SGA medications are subsidised for the treatment of schizophrenia, bipolar 
disorder and autism. The aim of this study was to examine the national trends 
in dispensed use of government-subsidised SGAs to children and youth aged 
less than 25 years between 2002 and 2007. Furthermore, we highlight the 
deficiencies in available data in order to encourage more accurate monitoring 
of psychotropic medication prescribing to children and adolescents.  
 
Methods 
In 2008 we requested data on the number of dispensed prescriptions in 
Australia for SGA medications from the Australian Government’s Department 
of Health and Ageing. We obtained the Medicare Australia records of 
prescriptions submitted for payment of a subsidy under the Pharmaceutical 
Benefits and Repatriation Pharmaceutical Benefits Schemes (PBS/RPBS).12 
From these data, we published the trends in prescribing of SGAs in the adult 
population.13 In 2011, we requested more recent data for children and youth 
under 25 years but this request was refused. Hence the data presented here is 
the best available from the Australian Government as of 2012.  
 Between 2002 and 2007, six SGAs were subsidised by the PBS: olanzapine, 
risperidone, quetiapine, amisulpride, aripiprazole and clozapine. In 2002, all of 
these SGAs were subsidised by the PBS for the treatment of schizophrenia 
except aripiprazole, which was subsidised later in 2004. In 2007 risperidone 
was subsidised for the treatment of severe behavioural disturbances 
associated with autism in patients aged less than18 years. Various SGAs were 
subsidised for the treatment of bipolar disorder (olanzapine in 2005, 
risperidone in 2006 and quetiapine in 2007).  
 
Although all SGAs of interest were subsidised for those whose diagnoses met 
the authority restrictions, it was also possible to obtain a private prescription 
to use these drugs to treat other disorders (i.e. anxiety, depression, disruptive 
behavioural disorders) at full cost to the patient. Medicare Australia did not 
collect data on private prescriptions and so the gender and age of persons 
receiving private scripts for these drugs were not included in our study.  
 
De-identified data on subsidised scripts included details of the drug product 
dispensed and information on the patient’s gender and age. The use of 
prescription medicines dispensed to inpatients in public hospitals was not 
available.  
 
The quantity of each drug dispensed was standardised using the defined daily 
dose (DDD) per 1000 population per day (DDD/1000 population/day). The 
DDD, established by the World Health Organisation Collaborating Centre for 
Drug Statistics Methodology, corresponds to an estimated average daily dose 
used for a medication’s principal indication in adults.14 Age-standardised drug 
utilisation for females and males was calculated for the period June 2002 to 
June 2007 (with appropriate half-year adjustment) using census mid-year 
population data.15 Data on the gender and age of persons receiving a 
prescription were not available before 2002, when a patient’s date of birth was 
first verified when dispensing drugs. All calculations were completed using 
Microsoft Office Excel 2007.  
 
Results 
According to the available data, dispensed use of SGAs in children aged 0–14 
years remained stable over the five-year study period (Figure 1). In 2007, total 
dispensed use of SGAs in children was 0.25 DDD/1000 population/day. This 
equates to fewer than three children in 10,000 persons younger than 15 years 
receiving a standard adult dose of medication each day. Risperidone was the 
most commonly dispensed drug between 2002 and 2007, accounting for 52% 
of all SGAs dispensed to children. Dispensed SGA use in Australian youth (15–
24 years) was approximately 24-fold higher than in children (Figure 2). 
Dispensed use of SGAs increased 12.5% from 5.61 to 6.31 DDDs/1000 
population/ day between 2002 and 2007.  
 
Figure 1.  
Dispensed drug utilisation (DDD/1000 population/day) by year for patients 
aged 0 to 14 years for selected SGA medications. 
SGA: second-generation antipsychotic. 
 
Figure 2.  
Dispensed drug utilisation (DDD/1000 population/day) by year for patients 
aged 15 to 24 years for selected SGA medications. 
SGA: second-generation antipsychotic. 
 
The trends in dispensed use of subsidised SGAs between 2002 and 2007 
differed by age and gender. In children, dispensed SGA use was highest in 
males between 10 and 14 years. This increased by 40% from 0.30 to 0.42 
DDD/1000 population/day between 2002 and 2007 (Figure 3).  
 Figure 3.  
Dispensed drug utilisation (DDD/1000 population/day) by year for males and 
females aged 0 to 4, 5 to 9 and 10 to 14 years for selected SGAs combined.  
SGA: second-generation antipsychotic. 
 
In Australian youth, males aged between 20 and 24 had the highest dispensed 
SGA use: 6.48 DDD/1000 population/day in 2007 (Figure 4). This equates to six 
in every 1000 Australian males aged 20 to 24 years being dispensed a standard 
adult dose of a subsidised SGA. In those aged between 15–19 years in 2007, 
there was approximately four times more dispensed SGA use in males than 
females, whereas in youth aged between 20 and 24 there was a twofold 
difference between males and females (Figure 4).  
 
Figure 4.  
Dispensed drug utilisation (DDD/1000 population/day) by year for males and 
females aged 15 to 19 and 20 to 24 years for selected SGAs combined.  
SGA: second-generation antipsychotic. 
 
Discussion 
The total dispensed use of subsidised SGAs by children less than 15 years of 
age remained stable between 2002 and 2007. This is in contrast to studies 
reporting increased rates of antipsychotic medication use among children and 
adolescents in the US, the UK, Iceland and Germany.9,11,16,17 The most likely 
explanation is that the available data captured only publicly subsidised 
prescriptions for SGAs that were used for the approved indications of 
schizophrenia, bipolar disorder and, in 2007, autism. In privately insured 
children (2–18 years) in the US, SGAs were most commonly prescribed for 
disruptive behaviour disorders (67%), mood disorders (65%) and anxiety 
disorders (43%).18 SGAs are not subsidised for any of these indications in 
Australia.  
 
Despite the increase in dispensed use of SGAs in children aged 10 to 14 years 
of both sexes, there remained a very low rate of dispensing at the end of the 
study period. In 2007, approximately 34 in every 100,000 Australian children 
(0.034%) received a defined daily (adult) dose of subsidised SGA medication. 
By comparison, during 2007, approximately 700 in every 100,000 Australian 
children under 14 years were dispensed a stimulant.19 Although there are no 
Australian prevalence studies of childhood schizophrenia, those from other 
countries have reported the prevalence rate of schizophrenia in children under 
15 years to be less than 10 in 100,000.20,21 The limited dispensed use of SGAs 
under PBS subsidy is commensurate with the very low prevalence of 
schizophrenia in children.  
 
This study highlights the deficiencies of the pharmacoepidemiology data that 
we accessed. Surprisingly in Australia, a developed nation with a sophisticated 
publicly subsidised health system, there are major limitations in accessing the 
available data. It is almost certain that there were a substantial number of 
prescriptions for SGAs in children for the management of disruptive behaviours 
.18,22 Although 92% of all SGA prescriptions in Australia are government 
subsidised,13 we cannot calculate the proportion of private prescriptions 
dispensed to children and adolescents. We could not determine other 
characteristics of children and youth prescribed SGAs beyond gender and age. 
There was no information on the indications for SGA prescribing and on 
whether they were co-prescribed with other psychotropic medications. 
Dispensed use may not reflect actual medication consumption. As the DDDs 
are standardised to the maintenance dose in adults, it is likely that the lower 
dose of medication prescribed to children (compared to adults) contributes, in 
part, to the very low rates of dispensed use. Therefore, the data presented 
here, especially for young children, are likely to substantially underestimate 
actual use. Finally, it is a concern that we were unable to access more recent 
data from the Australian Government Department of Health and Ageing.  
 This study emphasises the need to collect and make available more 
comprehensive data (i.e. subsidised and non-subsidised) on the use of all 
medications in children and young people in Australia. Access to these would 
improve monitoring of prescribing trends to children and adolescents and 
assist in supporting the quality use of medicines in this population.  
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